Underlying Problems in Surgical Treatment of cT1-2N1 Non-Small Cell Lung Cancer

Abstract

Background Obtaining an accurate preoperative diagnosis of N1 in non-small cell lung cancer (NSCLC) is a major difficulty. The aim of this retrospective study was to evaluate the pathological and long-term outcomes of NSCLC patients clinically staged with N1 disease, to aid in the search for better treatment strategies.

Materials and Methods We retrospectively reviewed the clinical records of 1,180 consecutive patients with NSCLC who underwent surgery for curative intent from 1991 to 2011 in our department. Data on 96 (8.1%) patients who had cT1–2N1 disease and underwent lobectomy or more extensive surgery were available.

Results Only 32% of patients (n = 31) were confirmed to have pathological N1 disease, and 34 and 33% of patients were proven to have pN0 and pN2 disease, respectively. Female gender, ≤ 30 pack-year tobacco smoking history, adenocarcinoma, and left-sided disease were significantly associated with pathological upstaging (χ ² test). Multivariate analysis using logistic regression revealed left-sided disease to be independently associated with upstaging (relative risk 4.00, p = 0.015). Left-sided disease was more likely to be underestimated by clinical N staging than right-sided disease (χ ² test, p = 0.0001). Univariate and multivariate survival analyses demonstrated that left-sided disease was an independent prognostic factor associated with poor outcomes (Cox proportional hazards regression: hazard ratio 2.27, p = 0.037).

Conclusion The diagnostic accuracy of clinical N1 status was poor. Left-sided disease appeared to be understaged by the preoperative assessment of N status, and therefore, patients who might benefit from preoperative induction treatment would not receive it.

Keywords

lung cancer treatment - diagnosis - tumor

• References

• 1 Rusch VW, Crowley J, Giroux DJ , et al; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2 (7) 603-612
• 2 Sawabata N, Miyaoka E, Asamura H , et al; Japanese Joint Committee for Lung Cancer Registration. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 2011; 6 (7) 1229-1235
• 3 Cerfolio RJ, Bryant AS. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Ann Thorac Surg 2007; 84 (1) 182-188 , discussion 189–190
• 4 Fujimoto T, Cassivi SD, Yang P , et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg 2006; 132 (3) 499-506
• 5 Demir A, Turna A, Kocaturk C , et al. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer. Ann Thorac Surg 2009; 87 (4) 1014-1022
• 6 Shin S, Kim HK, Choi YS, Kim K, Kim J, Shim YM. Prognosis of unexpected and expected pathologic N1 non-small cell lung cancer. Ann Thorac Surg 2013; 96 (3) 969-975 , discussion 975–976
• 7 Li ZM, Ding ZP, Luo QQ , et al. Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer. Chest 2013; 144 (4) 1253-1260
• 8 Arriagada R, Auperin A, Burdett S , et al; NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375 (9722) 1267-1277
• 9 NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383 (9928): 1561-1571
• 10 Okamoto T, Suzuki Y, Fujishita T , et al. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer—differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer 2014; 85 (2) 125-130
• 11 Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. Ann Thorac Surg 2005; 79 (5) 1682-1685
• 12 Hishida T, Yoshida J, Nishimura M, Nishiwaki Y, Nagai K. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax 2008; 63 (6) 526-531
• 13 Miyoshi K, Mimura T, Iwanaga K, Adachi S, Tsubota N, Okada M. Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today 2010; 40 (5) 428-432
• 14 Pignon JP, Tribodet H, Scagliotti GV , et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21) 3552-3559
• 15 Pisters KM, Vallières E, Crowley JJ , et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010; 28 (11) 1843-1849
• 16 Scagliotti GV, Pastorino U, Vansteenkiste JF , et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30 (2) 172-178
• 17 Shields TW. Lymphatics of the Lungs (Chapter 6). In: Shields TW, Locicero III J, Reed CE, Feins RH, , eds. General Thoracic Surgery, 7th ed. Philadelphia, PA: Lippincott; 2009: 87-101
• 18 Nohl-Oser HC. An investigation of the anatomy of the lymphatic drainage of the lungs as shown by the lymphatic spread of bronchial carcinoma. Ann R Coll Surg Engl 1972; 51 (3) 157-176
• 19 Carrillo SA, Daniel VC, Hall N, Hitchcock CL, Ross Jr P, Kassis ES. Fusion positron emission/computed tomography underestimates the presence of hilar nodal metastases in patients with resected non-small cell lung cancer. Ann Thorac Surg 2012; 93 (5) 1621-1624
• 20 Silvestri GA, Gonzalez AV, Jantz MA , et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e211S-e250S
• 21 Yasufuku K, Nakajima T, Waddell T, Keshavjee S, Yoshino I. Endobronchial ultrasound-guided transbronchial needle aspiration for differentiating N0 versus N1 lung cancer. Ann Thorac Surg 2013; 96 (5) 1756-1760